Actinogen appoints new director

Latest News

Actinogen Medical (ASX:ACW) has appointed Malcolm McComas as a non-executive director.

The company said Mr McComas brings over 25 years of experience in the financial services industry with extensive experience in corporate finance, M&A, debt and equity funding transactions across multiple industry sectors.

He previously held senior leadership roles with Grant Samuel, County NatWest (now Citigroup) and Morgan Grenfell (now Deutsche Bank) in Australia and the UK. Prior to this, Mr McComas was a lawyer at Herbert Geer, specialising in tax.

Mr McComas is an experienced company director and currently serves as Chairman of Pharmaxis (ASX:PXS) and Fitzroy River Corporation (ASX:FZR), and as a director of Saunders International (ASX: SND) and Royalco Resources (ASX: RCO).

He also has not-for-profit involvement as a director the Australasian Leukemia and Lymphoma Group and peak body experience as a former president of the Financial Services Institute of Australia (FINSIA). He is a Fellow of the Australian Institute of Company Directors and holds degrees in Law and Economics from Monash University in Melbourne.

“We are delighted to welcome Malcolm to the Actinogen Board. His experience in financial services, specifically in transactional and funding matters, will be of significant value as Actinogen enters the next phase of growth," said Actinogen Chairman, Dr Geoff Brooke. 

"The appointment of Malcom is highly complementary to the Board’s existing mix of skills and experience and we look forward to his contribution.”

The company said that, as a condition of his appointment, Mr McComas will be granted 3 million options, subject to shareholder approval, if required. The exercise price of the options will be $0.10 per option.